Analysts Viewpoint Cullinan Therapeutics Inc (CGEM) receives a Buy rating from H.C. Wainwright Cullinan Therapeutics Inc’s recently made public that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $4.19